San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea Pharmaceutica ...
In 1928, Alexander Fleming discovered penicillin, which would become the first commercialized antibiotic. Ever since, germs have...
West Coast, USA-based Forge Therapeutics has inked a deal with Switzerland's Basilea Pharmaceutica to...
San Diego’s Forge Therapeutics has partnered with Basilea Pharmaceutica to develop antibiotics for the Swiss drug company. The deal gives Forge the opportunity ...
Forge Therapeutics, founded in 2015 with the goal of developing drugs that target metalloenzymes, said Wednesday it had agreed to let Basilea Pharmaceutica ...
-Presentation will focus on Forge’s novel chemistry platform, BLACKSMITH, and its therapeutic applications- San Diego, California, March 12, 2019 – Forge Therapeutics, Inc. ...
As strains of bacteria evolve to fight back against common antibiotics, a slew of biotechnology companies are working to develop ways to combat ...
San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that it ...
